Literature DB >> 21866328

Use of long autologous nerve grafts in brachial plexus reconstruction: factors that affect the outcome.

Mariano Socolovsky1, Gilda Di Masi, Danilo Battaglia.   

Abstract

BACKGROUND: Using grafts directed to distal targets in brachial plexus reconstruction has the advantage over proximal targets of avoiding axonal dispersion. A long graft (more than 10 cm) is needed to reach most distal targets. The objective of this article is to identify factors associated with good versus poor outcomes in a clinical series of long grafts used for distal brachial plexus reconstruction.
METHODS: In 34 patients with a flail arm, 47 sural grafts >10 cm long were followed for ≥2 years postoperatively. Surgical technique included standard supraclavicular exposure of the proximal brachial plexus and its branches, the phrenic nerve and spinal accessory nerve. Distal target nerves were exposed via an incision starting at the axilla, following the gap between the biceps and triceps. Cases achieving a good result were statistically compared against those with a poor result as to the donor nerve/root, target nerve, patient age and weight, time from trauma to surgery, graft length and long-term rehabilitation quality.
FINDINGS: A good outcome was observed with 23 grafts (48.9%), but 66.7% of the 30 long grafts done within 6 months of trauma yielded a good result. Only 1 of 15 patients with the lowest quality rehabilitation score experienced a good result (6.6%) versus all 12 patients with the highest rating (p < 0.001). Trauma-to-surgery time was roughly half as long in those with a good result (4.7 vs. 9.0 months, p < 0.001). No other inter-group differences were observed.
CONCLUSIONS: The results of a series of distal brachial plexus target reinnervations with long grafts is presented and analyzed. According to them, time from trauma to surgery and an adequate postoperative rehabilitation are important predictors of outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21866328     DOI: 10.1007/s00701-011-1131-1

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  7 in total

1.  Timing of rehabilitation in children with obstetric upper trunk brachial plexus palsy.

Authors:  Volkan Yilmaz; Ebru Umay; Nihal Tezel; Ibrahim Gundogdu
Journal:  Childs Nerv Syst       Date:  2018-04-05       Impact factor: 1.475

2.  Alternatives to sural nerve grafts in the upper extremity.

Authors:  Louis H Poppler; Kristen Davidge; Johnny C Y Lu; Jim Armstrong; Ida K Fox; Susan E Mackinnon
Journal:  Hand (N Y)       Date:  2015-03

3.  Increasing Nerve Autograft Length Increases Senescence and Reduces Regeneration.

Authors:  Gwendolyn M Hoben; Xueping Ee; Lauren Schellhardt; Ying Yan; Daniel A Hunter; Amy M Moore; Alison K Snyder-Warwick; Sheila Stewart; Susan E Mackinnon; Matthew D Wood
Journal:  Plast Reconstr Surg       Date:  2018-10       Impact factor: 4.730

4.  Nerve transfer with 3D-printed branch nerve conduits.

Authors:  Jing Zhang; Jie Tao; Hao Cheng; Haofan Liu; Wenbi Wu; Yinchu Dong; Xuesong Liu; Maling Gou; Siming Yang; Jianguo Xu
Journal:  Burns Trauma       Date:  2022-04-15

Review 5.  A literature review of intercostal-to-musculocutaneous-nerve transfers in brachial plexus injury patients: Does body mass index influence results in Eastern versus Western countries?

Authors:  Mariano Socolovsky; Miguel Domínguez Paez
Journal:  Surg Neurol Int       Date:  2013-11-27

6.  Acellular nerve grafts supplemented with induced pluripotent stem cell-derived exosomes promote peripheral nerve reconstruction and motor function recovery.

Authors:  Jianfeng Pan; Meng Zhao; Xiangjiao Yi; Jianguo Tao; Shaobo Li; Zengxin Jiang; Biao Cheng; Hengfeng Yuan; Feng Zhang
Journal:  Bioact Mater       Date:  2021-12-20

Review 7.  Evidence-Based Approach to Timing of Nerve Surgery: A Review.

Authors:  Brendan J MacKay; Cameron T Cox; Ian L Valerio; Jeffrey A Greenberg; Gregory M Buncke; Peter J Evans; Deana M Mercer; Desirae M McKee; Ivica Ducic
Journal:  Ann Plast Surg       Date:  2021-09-01       Impact factor: 1.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.